Anbio Biotechnology NNNN
Biotechnology: In Vitro & In Vivo Diagnostic Substances · IPO 2025 · data as of November 13, 2026
Anbio Biotechnology (NNNN) is a healthcare company listed in the US with a market value of about $550M. In fiscal year 2025 it had revenue of $9M and net income of $6M, a net margin of 74.1%.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: a P/E of 85.8, a 5-year average ROIC of 27%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 87% below the current price.
About Anbio Biotechnology
Anbio Biotechnology is listed in the US and classified in biotechnology: in vitro & in vivo diagnostic substances, IPO year 2025. Revenue went from $24M in 2022 to $9M in 2025, a decline of about 28.4% a year. It was profitable in 4 of the last 4 years in our data. It spends 2% of revenue on research and development.
Score: 1.4 / 5
Checks passed
- Profit margin improving
- 5-year average ROIC above 12%
- ROE above 15%
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 4 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $9M | $8M | $7M | $24M |
| Net income | $6M | $2M | $2M | $10M |
| Free cash flow | — | — | — | — |
| EPS (diluted) | $0.04 | $0.02 | $0.02 | $0.07 |
| Net margin | 74.1% | 29.0% | 33.6% | 42.5% |
| ROIC | 19.1% | 11.6% | 13.2% | 64.2% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
What is Anbio Biotechnology’s P/E ratio?
About 85.8, based on the last twelve months of diluted earnings per share.
Is Anbio Biotechnology stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 87% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Anbio Biotechnology pay a dividend?
Not currently.
Is Anbio Biotechnology a good stock to buy?
We do not give buy or sell advice. Anbio Biotechnology scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.